Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The underlying diseases were classified as chronic obstructive pulmonary disease (COPD)/emphysema, cystic fibrosis ... less likely to be on long-term oxygen therapy. In the peri-transplantation ...

I’ve breathed pure oxygen in pressurised hyperbaric coffins ... The tests did provide some determinants however, such as whether he had the cystic fibrosis gene. “But I would have known that by now ...

Vertex Pharmaceuticals specializes in developing therapies to treat cystic ... fibrosis and progressive pulmonary fibrosis, other diseases that disrupt the lungs' ability to transfer oxygen ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

It also has activity against 31 CFTR variants — carried by around 150 cystic fibrosis patients in the US — that are not responsive to the older combination therapy. The new combination was ...

Louise Patterson, from Bray, is the mother of Aaron, who will soon be 12. His rare gene means he is currently excluded from modulator therapy Kaftrio, which, when combined with other medication ...